US4012285A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Analysis of isoenzyme patterns
Assignee: Merck Patent GmbH
•
Filing: 1973-11-27
•
Granted: 1977-03-15
•
Expires: 1993-11-27
Abstract
Abstract Isoenzyme patterns of an enzyme in biological fluids, extracts, and/or excretions are quantitatively determined by precipitating at least 90% of an isoenzyme antigen with a corresponding heterologous antiserum and comparing the remaining enzyme activity with the total activity with the use of a conventional agent for enzyme activity determination.
Inventors
- 👤 Gerhard Pfleiderer
- 👤 Hermann Lang
- 👤 Norbert Hennrich
- 👤 Hans Dieter Orth
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 13:06
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/573; Y; Y10; Y10S; Y10S436/00; Y10S436/811
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
203 words
A process for the quantitative determination of at least one diagnostically relevant isoenzyme form of a human enzyme occuring in a plurality of genetically defined, immunologically differentiable multiple isoenzyme forms, which comprises: a. quantitatively measuring the total enzyme activity of said multiple isoenzyme forms in a human body fluid, tissue extract or excretion sample; b. admixing a portion of said sample with a one to tenfold theoretical excess, based on the amount of antisera to the human isoenzyme antigens required to precipitate at least 90% of said antigens, of a precipitating antibody against an isoenzyme group of a heterologous species corresponding to a diagnostically relevant isoenzyme form, which antibody is substantially free of immunological activity against other of said multiple isoenzyme forms, to produce a substantially quantitative antigen-antibody immunoprecipitin complex consisting essentially of said diagnostically relevant human isoenzyme form and said antibody; c. substantially quantitatively separating said immunoprecipitin complex from the resultant admixture so that at least 90% of the diagnostically relevant human isoenzyme form activity is removed therefrom; and d. quantitatively measuring the total enzyme activity of the remaining multiple isoenzyme forms substantially free of the diagnostically relevant human isoenzyme form, whereby the diagnostically relevant human isoenzyme form can be quantitatively determined.
Claim 2
Dependent Claim
203 words
A process for the quantitative determination of at least one diagnostically relevant isoenzyme form of a human enzyme occuring in a plurality of genetically defined, immunologically differentiable multiple isoenzyme forms, which comprises: a. quantitatively measuring the total enzyme activity of said multiple isoenzyme forms in a human body fluid, tissue extract or excretion sample; b. admixing a portion of said sample with a one to tenfold theoretical excess, based on the amount of antisera to the human isoenzyme antigens required to precipitate at least 90% of said antigens, of a precipitating antibody against an isoenzyme group of a heterologous species corresponding to a diagnostically relevant isoenzyme form, which antibody is substantially free of immunological activity against other of said multiple isoenzyme forms, to produce a substantially quantitative antigen-antibody immunoprecipitin complex consisting essentially of said diagnostically relevant human isoenzyme form and said antibody; c. substantially quantitatively separating said immunoprecipitin complex from the resultant admixture so that at least 90% of the diagnostically relevant human isoenzyme form activity is removed therefrom; and d. quantitatively measuring the total enzyme activity of the remaining multiple isoenzyme forms substantially free of the diagnostically relevant human isoenzyme form, whereby the diagnostically relevant human isoenzyme form can be quantitatively determined.
Claim 3
Dependent Claim
17 words
A process according to claim 1 wherein said precipitation is further aided by an auxiliary non-immunological precipitant.
Claim 4
Dependent Claim
19 words
A process according to claim 2 wherein said auxiliary precipitant is a carrier on which said antiserum is fixed.
Claim 5
Dependent Claim
19 words
A process according to claim 1 wherein the isoenzyme antigen which is precipitated is a single diagnostically relevant isoenzyme.
Claim 6
Dependent Claim
19 words
A process according to claim 1 wherein at least one isoenzyme of said isoenzyme group is a hybrid isoenzyme.
Claim 7
Dependent Claim
40 words
A process according to claim 1 wherein said isoenzymes are those of an enzyme selected from the group consisting of aldolase, creatine kinase, lactate dehydrogenase, alkaline phosphatase, acidic phosphatase, γ-glutamyl transpeptidase, glutamate oxalacetate transaminase, glutamate pyruvate transaminase, hexokinase and amylase.
Claim 8
Dependent Claim
11 words
A process according to claim 6, wherein said enzyme is aldolase.
Claim 9
Dependent Claim
12 words
A process according to claim 6, wherein said enzyme is creatine kinase.
Claim 10
Dependent Claim
12 words
A process according to claim 6, wherein said enzyme is alkaline phosphatase.
Claim 11
Dependent Claim
12 words
A process according to claim 6, wherein said enzyme is acid phosphatase.
Claim 12
Dependent Claim
12 words
A process according to claim 6, wherein said enzyme is lactate dehydrogenase.
Claim 13
Dependent Claim
108 words
A process according to claim 1, wherein the reagents employed consist essentially of: a. A test set of individual heterologous immunoprecipitating antisera directed against the corresponding individual diagnostically relevant isoenzymes of the isoenzyme pattern to be tested, which antisera are each substantially free of immunological activity against other of said isoenzyme forms, respectively precipitable to an extent of at least 90% with the isoenzyme antigens to be determined, and which antisera each result in a practically quantitative immunoprecipitin cross-reaction at a one- to tenfold excess, based on the homologous antiserum; and b. an isoenzyme substrate agent for determining enzyme activity of said isoenzyme prior to and after precipitation.
References Cited (Backward Citations)
US3817837A
Cited
US3932221A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-03-14 | 1980-09-13 | 1981-03-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-03-14 | 1984-09-13 | 1985-03-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-03-14 | 1988-09-13 | 1989-03-15 | $7700.00 | Window Closed / Lapsed |